Our findings not only establish SIRT5 as a therapeutic target for ischemic stroke but also show that the Tat‐SIRT5‐CTM peptide designed in the present study may represent a potential therapeutic candidate for ischemic stroke. Here, TAT is linked to ischemic stroke.